Zai Lab 合作伙伴百时美施贵宝宣布 Pivotal KRYSTAL-12 确认试验。 Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial.

百时美施贵宝 (BMY) 和再鼎实验室针对 KRAZATI (adagrasib) 治疗携带 KRASG12C 突变的非小细胞肺癌的 3 期 KRYSTAL-12 研究达到了无进展生存期的主要终点和总体缓解率的关键次要终点，超过了标准护理化疗。 Bristol Myers Squibb (BMY) and Zai Lab's Phase 3 KRYSTAL-12 study of KRAZATI (adagrasib) for non-small cell lung cancer with a KRASG12C mutation met its primary endpoint of progression-free survival and key secondary endpoint of overall response rate, surpassing standard-of-care chemotherapy. 再鼎医药计划向中国国家药品监督管理局提交阿达格拉西的新药上市申请，并在其他实体瘤的二期临床试验中显示出令人鼓舞的结果。 Zai Lab plans to submit an NDA for adagrasib to China's NMPA and has shown encouraging results in Phase 2 clinical trials for other solid tumors.